4,296 Shares in Novartis AG $NVS Acquired by Greenspring Advisors LLC

Greenspring Advisors LLC acquired a new position in shares of Novartis AG (NYSE:NVS) in the fourth quarter, HoldingsChannel.com reports. The institutional investor acquired 4,296 shares of the company’s stock, valued at approximately $592,000.

Other institutional investors have also added to or reduced their stakes in the company. Arlington Trust Co LLC acquired a new position in Novartis during the 4th quarter worth approximately $25,000. Measured Wealth Private Client Group LLC acquired a new position in Novartis during the 3rd quarter worth approximately $33,000. South Plains Financial Inc. increased its position in Novartis by 39.0% during the 3rd quarter. South Plains Financial Inc. now owns 271 shares of the company’s stock worth $35,000 after purchasing an additional 76 shares in the last quarter. Aventura Private Wealth LLC acquired a new position in Novartis during the 4th quarter worth approximately $45,000. Finally, Cornerstone Planning Group LLC increased its position in Novartis by 15,950.0% during the 4th quarter. Cornerstone Planning Group LLC now owns 321 shares of the company’s stock worth $47,000 after purchasing an additional 319 shares in the last quarter. 13.12% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on NVS. Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of Novartis in a report on Thursday, February 12th. Argus raised shares of Novartis from a “hold” rating to a “buy” rating and set a $180.00 target price on the stock in a report on Wednesday, March 11th. Weiss Ratings lowered shares of Novartis from a “buy (a-)” rating to a “buy (b)” rating in a report on Wednesday, April 29th. Morgan Stanley boosted their target price on shares of Novartis from $143.00 to $170.00 and gave the stock an “overweight” rating in a report on Thursday, March 26th. Finally, DZ Bank lowered shares of Novartis from a “strong-buy” rating to a “hold” rating in a report on Monday, February 9th. Seven investment analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Novartis has an average rating of “Hold” and an average target price of $141.20.

Novartis Trading Up 3.3%

NVS opened at $148.39 on Friday. The company’s 50 day moving average price is $149.60 and its two-hundred day moving average price is $147.26. The company has a debt-to-equity ratio of 0.96, a current ratio of 0.85 and a quick ratio of 0.65. Novartis AG has a fifty-two week low of $112.34 and a fifty-two week high of $170.46. The firm has a market capitalization of $283.14 billion, a price-to-earnings ratio of 21.26, a PEG ratio of 2.52 and a beta of 0.46.

Novartis (NYSE:NVS) last posted its quarterly earnings data on Monday, April 27th. The company reported $1.99 EPS for the quarter, missing analysts’ consensus estimates of $2.11 by ($0.12). Novartis had a net margin of 24.87% and a return on equity of 38.82%. The firm had revenue of $13.52 billion during the quarter, compared to the consensus estimate of $13.44 billion. During the same period in the prior year, the company posted $2.28 earnings per share. The company’s revenue for the quarter was down .9% compared to the same quarter last year. As a group, research analysts predict that Novartis AG will post 8.84 earnings per share for the current year.

Novartis Company Profile

Novartis is a Swiss multinational pharmaceutical company headquartered in Basel that researches, develops, manufactures and commercializes prescription medicines and related health-care products. Formed through the 1996 merger of Ciba-Geigy and Sandoz, Novartis operates globally and focuses on bringing therapeutics from discovery through clinical development to commercial markets worldwide.

The company’s activities center on innovative pharmaceuticals across several therapeutic areas, including oncology, immunology, cardiovascular and metabolic diseases, neuroscience and ophthalmology, alongside capabilities in advanced therapies such as biologics, cell and gene therapies.